Subscribe to RSS
DOI: 10.1055/s-0030-1253703
© Georg Thieme Verlag KG Stuttgart · New York
Nachweis hepatischer Mikrometastasen
Einsatz im Kontext der adjuvanten Chemotherapie und der Lebermetastasenchirurgie?Detection of hepatic micrometastases in the context of adjuvant chemotherapy and surgery for hepatic metastasesPublication History
eingereicht: 7.12.2009
akzeptiert: 4.5.2010
Publication Date:
19 May 2010 (online)

Zusammenfassung
Das kolorektale Karzinom gehört zu den drei häufigsten humanen Malignomen und zeigt eine altersabhängige Zunahme der Inzidenz. Das Überleben beim kolorektalen Karzinom wird durch das Auftreten von Lokalrezidiven sowie hämatogenen und lymphogenen Metastasen bestimmt. Die primäre Resektion von Lebermetastasen gelingt bei ∼ 20 – 25 % aller Patienten mit hepatischen Metastasen und geht mit einer 50 % Rezidivrate innerhalb von 23 Monaten einher. Die 5-Jahresüberlebensrate im Stadium UICC IV beträgt ohne Therapie nur 5 %, das mittlere Überleben 6 – 9 Monate. Dank der positiven Entwicklung der Chemotherapie und der zielgerichteten Therapien („targeted therapy”) während der letzten Dekade konnte das mittlere Überleben auf deutlich über 2 Jahre angehoben werden. Der Einsatz von Polychemotherapien in Kombination mit anti-angiogenetisch sowie anti-proliferativ wirkenden Biologicals führte außerdem zu einer signifikanten Zunahme der sekundären Resektabilität von Lebermetastasen. Trotz R0-Resektion von Lebermetastasen bleiben nur ca. 30 % der Patienten langfristig rezidivfrei. Zur optimalen Patientenselektion werden prognostische Scores, wie der Fong-Score, herangezogen. Limitiert wird die Resektabilität durch eine hohe Rezidivrate für welche vor allem ortsansässige Mikrometastasen (MM) und disseminierte Tumorzellen (DTC) verantwortlich gemacht werden. Das Ausmaß der disseminierten Tumorzellbelastung korrelierte hierbei signifikant mit dem Überleben und der Rezidivrate nach Resektion. Diese Mikrometastasen werden in aktuell laufenden adjuvanten Therapiestudien (z. B. MT 201) unter Einsatz von anti-EpCam Antikörpern angegriffen. Der DTC Nachweis könnte die bisher angewandten Scores sinnvoll ergänzen und in Zukunft im Rahmen von Studien die Indikation für eine adjuvante Antikörper-basierte (z. B. anti-EpCam) Therapie darstellen.
Abstract
Colorectal cancer is one of the three most frequent malignancies in humans. Survival is mainly determined by local recurrence, lymphatic and hematogenous dissemination. Primary liver resection for metastases is possible in ~20-25% of patients with hepatic metastases and results in a 50% recurrence rate within 23 months. The five-year survival without treatment in patients with UICC stage IV is only 5%, the mean survival 6-9 months. As a result of promising developments in chemotherapy and targeted therapies in the last decade, the mean survival rate has significantly improved to over more than two years. Furthermore, the use of polychemotherapy in combination with anti-angiogenic and anti-proliferative biologicals has resulted in a significant increase of secondary resectability of liver metastases. Despite of a R0-resection (i.e. resection with clear margins) of liver metastases, only 30% of patients remain free of recurrence in the long-term. Prognostic scores are used for optimal patient selection, e.g. the Fong-Score. Resection is often limited by a high number of recurrences: intrahepatic micrometastases and disseminated tumor cells (DTC) are suspected as the cause of their development. In this connection the load of disseminated tumor cells correlates significantly with the survival and recurrence rate after resection. These micrometastases are targets in current adjuvant treatment studies (e.g. MT 201) by using anti-EpCam antibodies. The detection of DTC can supplement the previously used scores and represents the indication for an adjuvant antibody-based treatment (e.g. anti-EpCam) in the context of clinical trials.
Schlüsselwörter
kolorektales Karzinom - Lebermetastasenchirurgie - Mikrometastasen - disseminierte Tumorzellen
Keywords
colorectal cancer - surgery for liver metastases - micrometastases - disseminated tumor cells
Literatur
- 1
Becker M, Nitsche A, Neumann C. et al .
Sensitive PCR method for the detection
and real-time quantification of human cells in xenotransplantation
systems.
Br J Cancer.
2002;
87
1328-1335
MissingFormLabel
- 2
Bilchik A J, Hoon D S, Saha S. et al .
Prognostic impact of micrometastases in
colon cancer: interim results of a prospective multicenter trial.
Ann Surg.
2007;
246
568-575; 575 – 577
MissingFormLabel
- 3
Bosch B, Guller U, Schnider A. et
al .
Perioperative detection of disseminated tumour
cells is an independent prognostic factor in patients with colorectal
cancer.
Br J Surg.
2003;
90
882-888
MissingFormLabel
- 4
Conzelmann M, Dieterle C P, Linnemann U, Berger M R.
Cytokeratin
20 and guanylyl cyclase C mRNA is largely present in lymph node
and liver specimens of colorectal cancer patients.
Int
J Cancer.
2003;
107
617-628
MissingFormLabel
- 5
Conzelmann M, Linnemann U, Berger M R.
Molecular detection of clinical colorectal cancer metastasis:
how should multiple markers be put to use?.
Int J Colorectal
Dis.
2005;
20
137-146
MissingFormLabel
- 6
Conzelmann M, Linnemann U, Berger M R.
Detection of disseminated tumour cells in the liver of cancer
patients.
Eur J Surg Oncol.
2005;
31
977-985
MissingFormLabel
- 7
Cui J H, Krueger U, Henne-Bruns D, Kremer B, Kalthoff H.
Orthotopic transplantation model of human gastrointestinal cancer
and detection of micrometastases.
World J Gastroenterol.
2001;
7
381-386
MissingFormLabel
- 8
De Jong M C, Pulitano C, Ribero D. et al .
Rates and patterns of recurrence following
curative intent surgery for colorectal liver metastasis: an international
multi-institutional analysis of 1669 patients.
Ann Surg.
2009;
250
440-448
MissingFormLabel
- 9
Fong Y, Cohen A M, Fortner J G. et al .
Liver resection for colorectal
metastases.
J Clin Oncol.
1997;
15
938-946
MissingFormLabel
- 10
Fong Y, Fortner J, Sun R L, Brennan M F, Blumgart L H.
Clinical score for predicting recurrence
after hepatic resection for metastatic colorectal cancer: analysis
of 1001 consecutive cases.
Ann Surg.
1999;
230
309-318
MissingFormLabel
- 11
Ikawa K, Terashima Y, Sasaki K, Tashiro S.
Genetic detection of liver micrometastases
that are undetectable histologically.
J Surg Res.
2002;
106
124-130
MissingFormLabel
- 12
Kato T, Yasui K, Hirai T. et
al .
Therapeutic results for hepatic metastasis of colorectal
cancer with special reference to effectiveness of hepatectomy: analysis
of prognostic factors for 763 cases recorded at 18 institutions.
Dis Colon Rectum.
2003;
46
S22-31
MissingFormLabel
- 13
Kienle P, Koch M, Autschbach F. et al .
Decreased detection rate of disseminated
tumor cells of rectal cancer patients after preoperative chemoradiation:
a first step towards a molecular surrogate marker for neoadjuvant
treatment in colorectal cancer.
Ann Surg.
2003;
238
324-330
MissingFormLabel
- 14
Koch M, Kienle P, Logan E. et
al .
Detection of disseminated tumor cells in liver
biopsies of colorectal cancer patients is not associated with a worse
prognosis.
Ann Surg Oncol.
2007;
14
810-817
MissingFormLabel
- 15
Konopke R, Distler M, Ludwig S, Kersting S.
Location of liver metastases
reflects the site of the primary colorectal carcinoma.
Scand
J Gastroenterol.
2008;
43
192-195
MissingFormLabel
- 16
Koyanagi K, Bilchik A J, Saha S. et al .
Prognostic relevance of occult nodal micrometastases
and circulating tumor cells in colorectal cancer in a prospective
multicenter trial.
Clin Cancer Res.
2008;
14
7391-7396
MissingFormLabel
- 17
Leonard G D, Brenner B, Kemeny N E.
Neoadjuvant chemotherapy before liver resection for patients
with unresectable liver metastases from colorectal carcinoma.
J Clin Oncol.
2005;
23
2038-2048
MissingFormLabel
- 18
Linnemann U, Schimanski C C, Gebhardt C, Berger M R.
Prognostic
value of disseminated colorectal tumor cells in the liver: results
of follow-up examinations.
Int J Colorectal Dis.
2004;
19
380-386
MissingFormLabel
- 19
Mitry E, Fields A L, Bleiberg H. et al .
Adjuvant chemotherapy after potentially
curative resection of metastases from colorectal cancer: a pooled
analysis of two randomized trials.
J Clin Oncol.
2008;
26
4906-4911
MissingFormLabel
- 20
Naundorf S, Preithner S, Mayer P. et al .
In vitro and in vivo activity of MT201,
a fully human monoclonal antibody for pancarcinoma treatment.
Int J Cancer.
2002;
100
101-110
MissingFormLabel
- 21
Nordgard O, Aloysius T A, Todnem K, Heikkila R, Ogreid D.
Detection of lymph node micrometastases in colorectal cancer.
Scand J Gastroenterol.
2003;
38
125-132
MissingFormLabel
- 22
Nordlinger B, Sorbye H, Glimelius B. et al .
Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40 983):
a randomised controlled trial.
Lancet.
2008;
371
1007-1016
MissingFormLabel
- 23
Portier G, Elias D, Bouche O. et al .
Multicenter randomized trial of adjuvant
fluorouracil and folinic acid compared with surgery alone after
resection of colorectal liver metastases: FFCD ACHBTH AURC 9002
trial.
J Clin Oncol.
2006;
24
4976-4982
MissingFormLabel
- 24
Poston G J, Adam R, Alberts S. et al .
OncoSurge: a strategy for improving resectability
with curative intent in metastatic colorectal cancer.
J
Clin Oncol.
2005;
23
7125-7134
MissingFormLabel
- 25
Prang N, Preithner S, Brischwein K. et al .
Cellular and complement-dependent cytotoxicity
of Ep-CAM-specific monoclonal antibody MT201 against breast cancer
cell lines.
Br J Cancer.
2005;
92
342-349
MissingFormLabel
- 26
Schimanski C C, Linnemann U, Arbogast R, Berger M R.
Extended staging
results from the detection of isolated tumor cells in the liver
of colorectal cancer patients.
Oncol Rep.
2001;
8
185-188
MissingFormLabel
- 27
Schimanski C C, Linnemann U, Berger M R.
Sensitive detection of K-ras mutations augments diagnosis of
colorectal cancer metastases in the liver.
Cancer Res.
1999;
59
5169-5175
MissingFormLabel
- 28
Schimanski C C, Linnemann U, Galle P R, Arbogast R, Berger M R.
Hepatic disseminated tumor cells in colorectal cancer UICC stage
4 patients: prognostic implications.
Int J Oncol.
2003;
23
791-796
MissingFormLabel
- 29
Schmiegel W, Reinacher-Schick A, Arnold D. et al .
[Update S3-guideline „colorectal
cancer” 2008].
Z Gastroenterol.
2008;
46
799-840
MissingFormLabel
- 30
Schuster R, Max N, Mann B. et
al .
Quantitative real-time RT-PCR for detection of
disseminated tumor cells in peripheral blood of patients with colorectal
cancer using different mRNA markers.
Int J Cancer.
2004;
108
219-227
MissingFormLabel
- 31
Stein T N, Berger M R.
Quantification
of liver metastases from LS174T human colorectal cancer cells in
nude rats by PCR.
Anticancer Res.
1999;
19
3939-3945
MissingFormLabel
- 32
Tobkes A I, Nord H J.
Liver biopsy:
review of methodology and complications.
Dig Dis.
1995;
13
267-274
MissingFormLabel
- 33
Topal B, Aerts J L, Roskams T. et al .
Cancer cell dissemination during curative
surgery for colorectal liver metastases.
Eur J Surg Oncol.
2005;
31
506-511
MissingFormLabel
- 34
Vogel I, Shen Y, Soeth E. et
al .
A human carcinoma model in athymic rats reflecting
solid and disseminated colorectal metastases.
Langenbecks
Arch Surg.
1998;
383
466-473
MissingFormLabel
- 35
Weitz J, Kienle P, Magener A. et
al .
Detection of disseminated colorectal cancer cells
in lymph nodes, blood and bone marrow.
Clin Cancer Res.
1999;
5
1830-1836
MissingFormLabel
- 36
Wigmore S J, Madhavan K, Redhead D N, Currie E J, Garden O J.
Distribution of colorectal liver metastases
in patients referred for hepatic resection.
Cancer.
2000;
89
285-287
MissingFormLabel
- 37
Yamaguchi K, Chijiiwa K, Torato N, Kinoshita M, Tanaka M.
Ki-ras codon 12 point and P53 mutations: a molecular examination
of the main tumor, liver, portal vein, peripheral arterial blood
and para-aortic lymph node in pancreatic cancer.
Am J
Gastroenterol.
2000;
95
1939-1945
MissingFormLabel
- 38
Yokoyama N, Shirai Y, Ajioka Y. et al .
Immunohistochemically detected hepatic
micrometastases predict a high risk of intrahepatic recurrence after
resection of colorectal carcinoma liver metastases.
Cancer.
2002;
94
1642-1647
MissingFormLabel
PD Dr. Carl C. Schimanski
Universitätsmedizin der Johannes
Gutenberg-Universität Mainz, I. Medizinische
Klinik und Poliklinik
Langenbeckstr. 1
55101
Mainz
Phone: 061317/17-7276
Fax: 06131/17-5595
Email: schimanski@1-med.klinik.uni-mainz.de